Perlmutter and Greig proposed for Ablynx board
This article was originally published in Scrip
Ablynx has put forward Drs Roger Perlmutter and Russell Greig as candidates to be appointed independent non-executive directors. The company will vote at the extraordinary general meeting of its shareholders at the beginning of November. Dr Perlmutter, currently a director of StemCells Inc and Immune Design Corporation, was previously executive vice-president of research and development at Amgen. Dr Greig spent the majority of his career at GlaxoSmithKline where he most recently served as president of pharmaceuticals international from 2003-2008.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.